Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.

The Journal of antimicrobial chemotherapy - 1 Apr 2011

Symons Jori, van Lelyveld Steven F L, Hoepelman Andy I M, van Ham Petra M, de Jong Dorien, Wensing Annemarie M J, Nijhuis Monique

Abstract excerpt

OBJECTIVES: Maraviroc is the first licensed chemokine co-receptor 5 (CCR5) co-receptor antagonist in clinical practice. It is currently being used in patients harbouring exclusively CCR5-tropic virus. The objective of the study was to investigate the impact of maraviroc on viruses with different co-receptor preferences in a patient with a dual/mixed (D/M) infection. METHODS: We present a case report of an HIV-1...

Topics

Anti-HIV Agents
Cell Line
Cyclohexanes
Genotype
HIV Infections
HIV-1
Humans
Male
Maraviroc
Middle Aged
Treatment Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Triazoles

Viral Tropism

Source

Identifiers

PMID: 21393136
DOI: 10.1093/jac/dkq535

Genes

CCR5
CXCR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Maraviroc is able to inhibit dual-R5 viruses in a dual/mixed HIV-1-infected patient.PMID 21393136Read ↗

Inhibition of dual/mixed tropic HIV-1 isolates by CCR5-inhibitors in primary lymphocytes and macrophages.Semantic proximity Read ↗

In vitro phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (maraviroc): TROPI-CO study.Semantic proximity Read ↗

Genotypic tropism testing: evidence-based or leap of faith?Semantic proximity Read ↗

Maraviroc: a review of its use in HIV infection and beyond.Semantic proximity Read ↗

<i>In vitro</i> phenotypic susceptibility of HIV-1 non-group M to CCR5 inhibitor (Maraviroc): TROPI-CO studySemantic proximity Read ↗

CCR5 Antagonists: Host-Targeted Antivirals for the Treatment of HIV InfectionSemantic proximity Read ↗

Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.Semantic proximity Read ↗

HIV-1 dual/mixed tropic isolates show different genetic and phenotypic characteristics and response to maraviroc in vitroSemantic proximity Read ↗

HIV tropism: diagnostic tools and implications for disease progression and treatment with entry inhibitorsSemantic proximity Read ↗

Update on clinical and methodological recommendations for genotypic determination of HIV tropism to guide the usage of CCR5 antagonists.Semantic proximity Read ↗

HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis.Semantic proximity Read ↗

Effect of maraviroc on non-R5 tropic HIV-1: refined analysis of subjects from the phase IIb study A4001029.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.